Welcome to our dedicated page for BridgeBio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BridgeBio Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BridgeBio Pharma's regulatory disclosures and financial reporting.
BridgeBio Pharma, Inc. is facilitating a secondary offering in which a KKR-affiliated selling stockholder is offering 5,000,000 shares of common stock. The shares are priced at $78.00 per share, implying an aggregate offering price of $390,000,000.00, with all net proceeds of approximately $387,075,000.00 going to the selling stockholder; BridgeBio receives no proceeds. Common stock outstanding will remain 195,492,997 shares before and after the transaction, so the deal represents existing holders changing hands rather than new issuance. The selling stockholder’s stake will decrease from 14,232,739 shares (7.3%) to 9,232,739 shares (4.7%). The prospectus supplement sits under a broader shelf that permits resales of up to 24,628,286 shares of common stock. Risk disclosures highlight potential stock price pressure from substantial resale activity, ongoing share price volatility typical of biopharma stocks, and the subordinated nature of common equity to existing and future indebtedness, as well as future potential dilution from additional equity offerings and conversion of preferred stock.
BridgeBio Pharma, Inc. reported sharply higher revenue while remaining loss‑making. For the quarter ended June 30, 2026, total revenue was $243.7 million, up from $110.6 million a year earlier, driven primarily by $222.4 million in net product revenue from Attruby/Beyonttra and expanding royalty income.
Research and development expense was $149.4 million and selling, general and administrative expense was $186.3 million, reflecting heavy investment in commercialization and late‑stage programs. Net loss attributable to common stockholders narrowed to $152.2 million (loss of $0.78 per share) from $181.9 million (loss of $0.95 per share) in the prior‑year quarter.
At June 30, 2026, BridgeBio held $677.9 million in cash and cash equivalents and $42.2 million in marketable securities, but carried $3.72 billion of total liabilities, including multiple convertible note series and $879.4 million in deferred royalty obligations, resulting in a total stockholders’ deficit of $2.50 billion. Operating activities used $268.4 million of cash in the first half, partly offset by net financing inflows, including issuance of 2033 convertible notes.
BridgeBio Pharma reported strong top-line growth for the quarter ended June 30, 2026, while remaining loss-making as it invests heavily in commercialization and late-stage R&D. Total revenues were $243.7 million, up from $110.6 million a year earlier, driven mainly by $222.4 million in U.S. Attruby net product revenue and higher royalties from BEYONTTRA in the EU and Japan.
Total operating costs and expenses rose to $350.8 million from $244.8 million, reflecting increased SG&A for the Attruby launch and pre-commercial spend for pipeline programs, plus higher R&D. Net loss attributable to common stockholders narrowed to $152.2 million, or $0.78 per share, compared to $181.9 million, or $0.95, in 2025.
Cash, cash equivalents and marketable securities were $720.2 million as of June 30, 2026, excluding a subsequent $1 billion preferred equity financing that closed July 1, 2026. Strategically, all three key NDAs are now in or submitted for FDA review, with PDUFA dates for BBP‑418 on November 27, 2026 and encaleret on May 8, 2027, and an NDA for oral infigratinib filed in achondroplasia.
BridgeBio Pharma Chief Accounting Officer Maricel Apuli sold 2,000 shares of Common Stock on July 30, 2026 at $80.06 per share in an open-market transaction under a Rule 10b5-1 sales plan adopted on September 8, 2025, and now directly holds 127,401 shares.
BridgeBio Pharma, Inc. is the subject of an Amendment No. 1 to Schedule 13G filed by Farallon Capital Management, L.L.C. and related entities and individuals (together, the “Reporting Persons”). The filing concerns the company’s Common Stock, par value $0.001 per share.
The Reporting Persons collectively report beneficial ownership of 10,743,063 Shares of BridgeBio Pharma, representing 5.5% of the outstanding common stock, with shared voting and shared dispositive power over these Shares and no sole voting or dispositive power. The Shares are held directly by a group of investment partnerships referred to as the Farallon Funds, for which Farallon Capital Management, L.L.C. serves as investment manager. The Farallon Funds have the right to receive dividends and sale proceeds from these securities.
BlackRock, Inc. reports its beneficial ownership of common stock of BridgeBio Pharma, Inc. on an amended Schedule 13G. BlackRock reports beneficial ownership of 9,733,762 shares, representing 4.96% of BridgeBio’s common stock, with sole voting power over 9,472,242 shares.
BlackRock also reports sole dispositive power over 9,733,762 shares and no shared voting or dispositive power. Various underlying clients have economic rights to dividends and sale proceeds, but no single person has an interest in more than five percent of BridgeBio’s outstanding common shares.
BridgeBio Pharma, Inc. has filed an automatic shelf registration on Form S-3 to replace an expiring Form S-3 and register the resale of up to 24,628,286 shares of common stock held by KKR Genetic Disorder L.P., Aisling Capital IV LP, Chinotto Investments, LLC, HCRx Investments HoldCo, L.P. and their affiliates under Registration Rights Agreements from 2019 and 2026. The registered shares include both outstanding common stock and shares issuable upon conversion of Series A Cumulative Convertible Participating Preferred Stock.
The company will not receive any proceeds from sales of these shares; all proceeds go to the selling stockholders, who may dispose of shares over time through various public or private transaction methods described under the plan of distribution. BridgeBio will cover registration-related fees and expenses.
BridgeBio is described as a commercial-stage, multi-product biopharmaceutical company focused on genetic diseases, generating material revenue from one approved product (acoramidis/Attruby/Beyonttra) and advancing late-stage candidates BBP-418 and encaleret, both with FDA NDAs accepted and assigned PDUFA target action dates.
BridgeBio Pharma, Inc. announced that the FDA has accepted for filing its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1), assigning a PDUFA target action date of May 8, 2027 and indicating it is not currently planning an advisory committee meeting.
The Phase 3 CALIBRATE trial of encaleret in ADH1 achieved all pre-specified primary and key secondary endpoints, and BridgeBio is enrolling the CALIBRATE-PEDS Phase 2/3 pediatric study and preparing a Phase 3 trial in chronic hypoparathyroidism. As of April 2026, over 2,100 individuals in the U.S. have been diagnosed with autosomal dominant hypocalcemia since October 2023 based on claims data, and the company plans to submit a European MAA for encaleret in the second half of 2026.
BridgeBio Pharma director Andrea Ellis reported an exercise-and-sale sequence involving 17167.0000 shares of common stock on July 9, 2026. She exercised stock options to acquire 17167.0000 shares at 16.7500 per share and sold 17167.0000 shares at 84.0000 per share in an open-market transaction pursuant to a Rule 10b5-1 sales plan adopted on December 3, 2025. The sale transaction line reports 22579.0000 common shares beneficially owned directly immediately following that sale.
BridgeBio Pharma, Inc. director Jennifer E. Cook reported an option exercise-and-sale sequence in common stock. On July 9, 2026, she exercised stock options covering 148,589 shares at exercise prices of $8.45, $16.75, and $29.00 per share, then sold 148,589 shares of common stock in open-market transactions at prices of $90.00 and $84.00 per share. The sales were effected pursuant to a Rule 10b5-1 sales plan adopted on March 16, 2026.